Peroxisome Proliferator-Activated Receptor γ Negatively Regulates Allergic Rhinitis in Mice

• Published in: Allergology international 2009-01, Vol.58 (2), p.247-253
• Main Authors: Fukui, Naoko, Honda, Kohei, Ito, Eiko, Ishikawa, Kazuo
• Format: Article
• Language: English
• Subjects: allergic rhinitis; Animals; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Behavior, Animal - drug effects; eosinophils; Eosinophils - metabolism; Eosinophils - pathology; Epithelial Cells - metabolism; Female; Histamine - pharmacology; Immunoglobulin E - blood; Immunoglobulin E - immunology; Interferon-gamma - metabolism; Interleukin-13 - metabolism; Interleukin-5 - metabolism; Mice; Mice, Inbred BALB C; murine model; Nasal Mucosa - drug effects; Nasal Mucosa - metabolism; Nasal Mucosa - pathology; ovalbumin; Ovalbumin - immunology; Ovalbumin - pharmacology; PPAR gamma - agonists; PPAR gamma - metabolism; Rhinitis, Allergic, Perennial - drug therapy; Rhinitis, Allergic, Perennial - immunology; Rhinitis, Allergic, Perennial - metabolism; Rhinitis, Allergic, Perennial - pathology; Sneezing - drug effects; Spleen - drug effects; Spleen - metabolism; Thiazolidinediones - administration & dosage; Thiazolidinediones - pharmacology; Thiazolidinediones - therapeutic use
• ISSN: 1323-8930; 1440-1592
• DOI: 10.2332/allergolint.08-OA-0047

Peroxisome proliferator-activated receptor γ (PPAR-γ) has been shown to play an important role in the control of inflammatory responses acting on macrophages, mast cells, T cells, and eosinophils. The present study was aimed at investigating the effects of PPAR-γ agonist on nasal symptoms and eosinophil accumulations in nasal mucosa by using a murine allergic rhinitis model. Furthermore, we examined the expression of PPAR-γ in the nasal mucosa in mice. BALB/c mice were sensitized and challenged intranasally with ovalbumin. Ciglitazone, a PPAR-γ agonist, was administered orally 6 hours before each nasal challenge. Administration of PPAR-γ agonist significantly decreased the number of nasal rubs, nasal histamine responsiveness, serum IgE, IL-5 production from the spleen, and eosinophilic infiltration in the nasal mucosa. Furthermore, PPAR-γ was expressed in eosinophils and epithelial cells in the nasal mucosa by immunohistochemistry. PPAR-γ was expressed in eosinophils and epithelial cells in the nasal mucosa. Also, the oral administration of ciglitazone is effective in upper airway allergic inflammation in mice.